STARD5: A Potential Drug Target and Biomarker (G80765)

Target Name: STARD5

NCBI ID: G80765

STARD5

STARD5: A Potential Drug Target and Biomarker

Introduction

Stroke is a leading cause of morbidity and mortality worldwide, affecting over 170 million people each year. The underlying cause of stroke is the disruption of blood flow to the brain, which can result in a range of devastating effects, including paralysis, loss of vision , and even death. Despite advances in stroke treatment, the survival rate remains poor, and the long-term effects of stroke can be devastating. Therefore, there is a need for new treatments and better diagnostic tools to improve outcomes.

STARD5 is a potential drug target and biomarker that has been identified as a promising candidate for stroke treatment. In this article, we will discuss the biology of stroke, the development of STARD5 as a drug target, and its potential as a biomarker for stroke.

The Biology of Stroke

Stroke is a complex disease that involves the disruption of blood flow to the brain. This disruption can occur due to a blockage of blood vessels, called ischemia, or the rupture of blood vessels, called hemorrhage. Ischemia is the most common cause of stroke, accounting for approximately 60% of cases, while hemorrhage accounts for the remaining 40%.

Stroke is a medical emergency and requires treatment as soon as possible. The severity of stroke can vary from mild to severe, with the latter being the most

Protein Name: StAR Related Lipid Transfer Domain Containing 5

Functions: May be involved in the intracellular transport of sterols or other lipids. May bind cholesterol or other sterols (By similarity)

The "STARD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STARD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets